The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesICC: Use at a concentration of 0.5 µg/ml.
IF: Use at a concentration of 0.5 µg/ml.
IHC-Fr: Use at a concentration of 0.5 µg/ml. This antibody gives a strong signal mainly in interneurons and astrocytes in the dentate region of rat hippocampal samples.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionProbably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs.
Tissue specificityPredominantly expressed in brain.
Involvement in diseaseDefects in KCNQ3 are the cause of benign neonatal epilepsy type 2 (EBN2) [MIM:121201]. Benign neonatal epilepsy is characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset.
Sequence similaritiesBelongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.3/KCNQ3 sub-subfamily.
DomainThe segment S4 is probably the voltage-sensor and is characterized by a series of positively charged amino acids at every third position.